Products with Pro-apoptotic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2359 | Telocinobufagin |
| Telocinobufagin is a novel endogenous digitalis, it shows a reversible local anesthetic action, similar to BUPI, however, without cardiac toxicity in vitro. Telocinobufagin has antimicrobial, potential immune system regulatory effects, it could be developed as a novel immunotherapeutic agent to treat and other immune-mediated diseases, and it may become a new immunomodulatory agent in many regions. | |
| BCN2376 | Vinblastine |
| Vinblastine is a cytotoxic alkaloid used against various cancer types. Vinblastine inhibits the formation of microtubule and suppresses nAChR with an IC50 of 8.9 μM.Vinblastine potently induced the proapoptotic protein PMAIP1 (NOXA) in both time- and dose-dependent manner and this was required for the observed apoptosis.The combination of antifungal azoles with Vinblastine can increase the incidence and severity of hyponatremia. Therefore, combined administration of azole antifungals with Vinblastine should be avoided. | |
| BCN2391 | Jolkinolide B |
| 1. Jolkinolide B can induce neuroendocrine differentiation of human prostate LNCaP cancer cell line. 2. Jolkinolide B can induce apoptosis in MDA-MB-231 cells through inhibition of the PI3K/Akt signaling pathway. 3. Jolkinolide B has potent anti-inflammatory activities, the mechanism may be attributed to its suppression of NF-κB and activation. 4. Jolkinolide B exhibits significant antitumor activity, it is able to enhance apoptosis of human leukemic HL-60 and THP-1 cells, at least in part, through downregulation of JAK2/STAT3 and bcl-2, and upregulation of Bax and cytosolic cytochrome c. | |
| BCN2416 | Cyclo(Phe-Pro) |
| Cyclo(Phe-Pro) inhibition of cholera toxin and toxin-coregulated pilus production correlated with reduced transcription of the virulence regulator tcpPH and was alleviated by overexpression of tcpPH.Cyclo(Phe-Pro) has been shown to inhibit cancer cell growth and induce apoptosis in HT-29 colon cancer cells. | |
| BCN2463 | Chelidonine |
| Chelidonine is a promising model compound for overcoming MDR and for enhancing cytotoxicity of chemotherapeutics, especially against leukaemia cells, its efficacy needs to be confirmed in animal models. Chelidonine may be a potential therapeutic agent against metastasis of invasive human cancer cells, exhibits anti‑migratory and anti‑invasive effects in MDA‑MB‑231 cells, by suppressing COL‑I‑induced integrin signaling, through inhibiting the formation of the IPP complex and subsequent down‑regulation of IPP downstream signaling molecules, such as Akt and ERK1/2. | |
